A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

BACKGROUND: Anlotinib is a multi-targeted tyrosine kinase inhibitor mainly targeting angiogenesis signaling. The predictive marker of anlotinib’s efficacy remains elusive. This study was designed to explore the predictive marker of anlotinib in non-small cell lung cancer (NSCLC). METHODS: We prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fei, Xu, Haiyan, Wan, Zhiyi, Yang, Guangjian, Yang, Lu, Wu, Xueying, Song, Jin, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777128/
https://www.ncbi.nlm.nih.gov/pubmed/35070967
http://dx.doi.org/10.3389/fonc.2021.756902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777128/
https://www.ncbi.nlm.nih.gov/pubmed/35070967
http://dx.doi.org/10.3389/fonc.2021.756902

Ejemplares similares